Cartesian Therapeutics initiated a phase 1 clinical trial for Descartes-15, a novel mRNA-engineered CAR-T therapy, in relapsed/refractory multiple myeloma patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.